StockDrifts LogoStockDrifts

Oreum Therapeutic 475830

Company
오름테라퓨틱Oreum Therapeutic
Insiders
2
Buys
0
Total Value
₩23.0B ($16.0M)
Avg Return
-75.51%
Last Filing
2026-06-01

Oreum Therapeutic (475830) has 0 disclosed insider purchases and 5 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩23.0B ($16.0M) in reported transaction value. The earliest filing StockDrifts holds for Oreum Therapeutic is dated 2025-02-14; the most recent is 2026-06-01. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is -75.51%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-06-01BUY주식매수선택권
김병우
Kim Byeong-woo
thanks3.3K₩63,700-0.8%₩210M ($146K)
2026-06-01BUY주식매수선택권
PETER UNNAM PARK
Other non-executive directors100.0K₩63,700-0.8%₩6.4B ($4.4M)
2026-03-25SELLMarket Sell
PETER UNNAM PARK
Other non-executive directors-9.0K₩112,100-0.3%₩1.0B ($701K)
2026-03-24SELLMarket Sell
PETER UNNAM PARK
Other non-executive directors-30.0K₩110,600-1.6%₩3.3B ($2.3M)
2025-12-01SELLMarket Sell
인터베스트
Intervest
--85.0K₩62,500-109.1%₩5.3B ($3.7M)
2025-11-28SELLMarket Sell
인터베스트
Intervest
--150.0K₩57,000-129.3%₩8.6B ($5.9M)
2025-11-27SELLMarket Sell
인터베스트
Intervest
--87.7K₩55,100-137.2%₩4.8B ($3.4M)
2025-02-14BUY신규상장
이승주
Seungju Lee
CEO3.4M₩21,800+499.5%₩73.9B ($51.3M)
2025-02-14BUY신규상장
PETER UNNAM PARK
Other non-executive directors60.0K₩21,800+499.5%₩1.3B ($908K)
2025-02-14BUY신규상장
정인태
Jeong In-tae
moving10.0K₩21,800+499.5%₩218M ($151K)
2025-02-14BUY신규상장
인터베스트
Intervest
-2.3M₩21,800+499.5%₩49.3B ($34.3M)

Frequently asked questions

Who has been buying Oreum Therapeutic stock?
2 distinct insiders have filed 0 disclosed insider purchases in Oreum Therapeutic (475830), most recently on 2026-06-01. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Oreum Therapeutic have?
Oreum Therapeutic has 0 buy-side and 5 sell-side disclosures on record, covering ₩23.0B ($16.0M) in total reported value, spanning 2025-02-14 to 2026-06-01.
Where does StockDrifts get Oreum Therapeutic insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Oreum Therapeutic. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.